Antibody immunosuppressive therapy in solid organ transplant

Klipa, Dusko; Mahmud, Nadim; Ahsan, Nasimul

doi:10.4161/mabs.2.6.13586

Cited by 30 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antisera to human T lymphocytes or thymocytes such as horse antilymphocyte globulin or rabbit antithymocyte globulin contain polyclonal antibodies that recognize many different T cell antigens and cause lymphodepletion by mechanisms similar to that of the monoclonal antibodies. Basiliximab, an antibody specific for the IL-2 receptor (CD25), does not cause similar T cell depletion, but it has synergy with calcineurin inhibitors [25,26].…”

Section: Induction Agentsmentioning

confidence: 99%

Immunology of Transplant Protocols

Gallay

DeMattos

2014

Curr Otorhinolaryngol Rep

View full text Add to dashboard Cite

The development of immunosuppressive medications to control the alloimmune response against donor Human leukocyte antigens (HLA) has permitted the transplantation of many solid organs as well as the treatment of graft versus host disease in bone marrow transplantation. The experience gained with these now routine therapies for end stage organ disease has led to protocols for composite tissue transplantation with grafts containing multiple organ types, such as skin, muscle, nerve, and bone. Successful transplant of limbs, face, and larynx has ushered in a new stage in the progress of clinical transplantation with identification of newly characterized interactions between the immune system and the allograft. The expanding number of clinically successful composite tissue transplants has increased the likelihood for subspecialists not in the traditional fields of nephrology, hepatology, pulmonology, or cardiology to encounter patients taking immunosuppressive medications. Therefore, it is useful to have a basic understanding of the rationale for and complications of therapies including these medications.

show abstract

Section: Induction Agentsmentioning

confidence: 99%

Immunology of Transplant Protocols

Gallay

DeMattos

2014

Curr Otorhinolaryngol Rep

View full text Add to dashboard Cite

show abstract

“…A variety of new treatments that include rituximab are currently being explored to deplete B-cell populations in the hopes of reducing acute rejection episodes and preserving long-term graft survival. 87 …”

Section: Kidney Transplantation: Antibody-mediated Rejectionmentioning

confidence: 99%

Rituximab in immunologic glomerular diseases

Ejaz

Asmar

Alsabbagh

et al. 2012

mAbs

Self Cite

View full text Add to dashboard Cite

“…There are preliminary data on the use of several other antibody drugs: epratuzumab targets CD22 expressed on B cells committed to antibody production [82]; belimumab inhibits B-lymphocyte stimulator and thus induces apoptosis and prevents immunoglobulin production [83]; tocilizumab binds the IL-6 receptor and is thought to inhibit the inflammatory response [84]; infliximab, already approved in the treatment of several autoimmune diseases, targets tumor necrosis factor and may play a role in the treatment of acute rejection [85].…”

Section: Newer Agentsmentioning

confidence: 99%